FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091849125> ?p ?o ?g. }

• W2091849125 endingPage "281" @default.
• W2091849125 startingPage "275" @default.
• W2091849125 abstract "Objectives. To assess the clinical response to luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix (SB-75) in patients with advanced carcinoma of the prostate and paraplegia due to mestastatic invasion of spinal cord. Methods. Cetrorelix was given at two different dose regimens to 5 patients with prostatic cancer Stage D2 and paraplegia. Urologic and neurologic examinations, laboratory studies, radiography (myelography), and prostate ultrasonography were carried out. Prostate-specific antigen (PSA) and free testosterone were also measured. Results. In all patients, the neurologic symptoms regressed. The recovery of the thermic and vibratory sensation and motility of the toes was observed. The neurologic improvement continued during the treatment and at 3 months all the patients were able to walk with the aid of a cane. In 1 patient, the myelography showed that the spinal cord compression had disappeared and prostate volume assessed by ultrasonography showed a significant decrease. The bladder function greatly improved in all 5 patients during the treatment with cetrorelix. Baseline levels of luteinizing hormone fell from 9.28 to 1.0 IU/L and those of follicle-stimulating hormone (FSH) fell from 18.28 to 12 IU/L (P < 0.05) after the first day of therapy with cetrorelix. Mean levels of free testosterone were reduced from 52.4 to 14.7 pmol/L (P < 0.005) at 12 hours and to 13.1 pmol/L (P < 0.005) 3 days after the first injection of cetrorelix. A persistent inhibition of gonadotropins and testosterone was maintained during the subsequent 3 months of therapy. The high levels of PSA gradually decreased. Conclusions. Our results show that LH-RH antagonist cetrorelix causes an immediate lowering of the serum testosterone levels in patients with prostate cancer and metastases in the spinal cord, in whom the LH-RH agonists cannot be used as single drugs because of the possibility of flare-up and appears to be appropriate for long-term therapy." @default.
• W2091849125 created "2016-06-24" @default.
• W2091849125 creator A5017788813 @default.
• W2091849125 creator A5040619933 @default.
• W2091849125 creator A5050046526 @default.
• W2091849125 creator A5056596376 @default.
• W2091849125 creator A5063296502 @default.
• W2091849125 creator A5065367273 @default.
• W2091849125 creator A5068739269 @default.
• W2091849125 date "1995-02-01" @default.
• W2091849125 modified "2023-10-18" @default.
• W2091849125 title "Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord" @default.
• W2091849125 cites W126379783 @default.
• W2091849125 cites W1971459148 @default.
• W2091849125 cites W1972020194 @default.
• W2091849125 cites W1976877206 @default.
• W2091849125 cites W1983355170 @default.
• W2091849125 cites W1986451811 @default.
• W2091849125 cites W1986504199 @default.
• W2091849125 cites W1990907410 @default.
• W2091849125 cites W2011455302 @default.
• W2091849125 cites W2019531477 @default.
• W2091849125 cites W2022008209 @default.
• W2091849125 cites W2038243639 @default.
• W2091849125 cites W2040997484 @default.
• W2091849125 cites W2050430224 @default.
• W2091849125 cites W2051202032 @default.
• W2091849125 cites W2051270818 @default.
• W2091849125 cites W2054344276 @default.
• W2091849125 cites W2063613304 @default.
• W2091849125 cites W2074140598 @default.
• W2091849125 cites W2088295630 @default.
• W2091849125 cites W2088718085 @default.
• W2091849125 cites W2129174433 @default.
• W2091849125 cites W2162805000 @default.
• W2091849125 cites W2405182767 @default.
• W2091849125 cites W2414676615 @default.
• W2091849125 cites W2418606207 @default.
• W2091849125 cites W2426149359 @default.
• W2091849125 cites W2465980388 @default.
• W2091849125 cites W2522707256 @default.
• W2091849125 cites W4234066336 @default.
• W2091849125 cites W4236477560 @default.
• W2091849125 cites W4244306117 @default.
• W2091849125 cites W4251307099 @default.
• W2091849125 doi "https://doi.org/10.1016/0090-4295(95)80018-2" @default.
• W2091849125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7531902" @default.
• W2091849125 hasPublicationYear "1995" @default.
• W2091849125 type Work @default.
• W2091849125 sameAs 2091849125 @default.
• W2091849125 citedByCount "60" @default.
• W2091849125 countsByYear W20918491252012 @default.
• W2091849125 countsByYear W20918491252013 @default.
• W2091849125 countsByYear W20918491252014 @default.
• W2091849125 countsByYear W20918491252015 @default.
• W2091849125 countsByYear W20918491252017 @default.
• W2091849125 countsByYear W20918491252018 @default.
• W2091849125 countsByYear W20918491252019 @default.
• W2091849125 countsByYear W20918491252021 @default.
• W2091849125 crossrefType "journal-article" @default.
• W2091849125 hasAuthorship W2091849125A5017788813 @default.
• W2091849125 hasAuthorship W2091849125A5040619933 @default.
• W2091849125 hasAuthorship W2091849125A5050046526 @default.
• W2091849125 hasAuthorship W2091849125A5056596376 @default.
• W2091849125 hasAuthorship W2091849125A5063296502 @default.
• W2091849125 hasAuthorship W2091849125A5065367273 @default.
• W2091849125 hasAuthorship W2091849125A5068739269 @default.
• W2091849125 hasConcept C118552586 @default.
• W2091849125 hasConcept C121608353 @default.
• W2091849125 hasConcept C126322002 @default.
• W2091849125 hasConcept C126894567 @default.
• W2091849125 hasConcept C2776235491 @default.
• W2091849125 hasConcept C2777597760 @default.
• W2091849125 hasConcept C2778575703 @default.
• W2091849125 hasConcept C2779279165 @default.
• W2091849125 hasConcept C2779279991 @default.
• W2091849125 hasConcept C2780192828 @default.
• W2091849125 hasConcept C2780775167 @default.
• W2091849125 hasConcept C2781406297 @default.
• W2091849125 hasConcept C71315377 @default.
• W2091849125 hasConcept C71924100 @default.
• W2091849125 hasConceptScore W2091849125C118552586 @default.
• W2091849125 hasConceptScore W2091849125C121608353 @default.
• W2091849125 hasConceptScore W2091849125C126322002 @default.
• W2091849125 hasConceptScore W2091849125C126894567 @default.
• W2091849125 hasConceptScore W2091849125C2776235491 @default.
• W2091849125 hasConceptScore W2091849125C2777597760 @default.
• W2091849125 hasConceptScore W2091849125C2778575703 @default.
• W2091849125 hasConceptScore W2091849125C2779279165 @default.
• W2091849125 hasConceptScore W2091849125C2779279991 @default.
• W2091849125 hasConceptScore W2091849125C2780192828 @default.
• W2091849125 hasConceptScore W2091849125C2780775167 @default.
• W2091849125 hasConceptScore W2091849125C2781406297 @default.
• W2091849125 hasConceptScore W2091849125C71315377 @default.
• W2091849125 hasConceptScore W2091849125C71924100 @default.
• W2091849125 hasIssue "2" @default.
• W2091849125 hasLocation W20918491251 @default.
• W2091849125 hasLocation W20918491252 @default.

• next